

**Remarks**

By this amendment the specification has been updated to reflect prior related applications, to include sequence identifiers, and to insert the abstract on a separate page.

Claims 1-54 were pending. By this amendment, claims 7, 9, 16, 30, 40, 42, 47-48, and 53 are cancelled. No new claims were added. Therefore, claims 1-6, 8, 10-15, 17-29, 31-39, 41, 43-46, 49-52, and 54 are now pending.

The claims were amended to comply with US practice, namely, to correct antecedent basis and minor typographical errors, to remove multiple dependencies, and to amend "use" claims. The claims were also amended to include the amendments made under Article 34 PCT. In addition:

Claim 1 was amended to clarify the claim. Support can be found on page 1, lines 3-4 of the specification.

Claim 8 was amended to include claim 9.


Claims 1, 2, 4, 28, 31, 35, and 39 were amended to include sequence identifiers.

No new matter has been added by this amendment.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

  
Sheree Lynn Rybak, Ph.D.  
Registration No. 47,913

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 228-9446